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current was 21 amps (range 13-35). No acute ECG or skin changes were observed.
Conclusions: This study confirms the safety and high first shock efficacy of the wave-
form in ventricular fibrillation. This new AED waveform delivers limited peak current in low
impedance patients and sufficient average current in high impedance patients for suc-
cessful defibrillation.
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Background: We evaluated how the timing of troponin (Tn) elevation in patients with
non–ST-elevation acute coronary syndromes (NSTE ACS) influences adherence to the
ACC/AHA Practice Guidelines and clinical outcomes.
Methods: In the CRUSADE Initiative, we compared treatment and outcomes in high-risk
NSTE ACS patients with baseline positive troponin (Tn+) (n = 12,342) to patients who
were Tn+ only on later samples (n = 7,086). Tn+ was defined as greater than the cut-off
value at each institution.
Results: Median time to the first Tn+ sample was 0.7 hours (0.3, 1.7 hours) in patients
with baseline Tn+ levels vs. 13.0 hours (8.4, 19.8) for patients with later Tn+ levels. Acute
medication use (<24 hrs) was similar between groups, but patients with baseline Tn+ lev-
els were less likely to undergo cardiac catheterization and percutaneous coronary inter-
vention (PCI ) than patients with later Tn+ levels (Table). Unadjusted and risk-adjusted
mortality rates were higher in patients with baseline Tn+ levels.
Conclusions: The use of Guidelines-recommended therapies was sub-optimal in all
NSTE MI patients with Tn+ levels. Paradoxically, patients identified as high-risk by base-
line Tn+ levels received no better acute care and were less likely to undergo cardiac
catheterization and PCI than patients with late Tn+ . Appropriate responses to elevated
troponins with guidelines-based interventions are needed to overcome such disparities.
Acute Medications (< 24 hours), Procedures, and Outcomes 
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Background: We have reported that cariporide (a selective inhibitor of the sodium-
hydrogen exchanger isoform-1) given during resuscitation from VF ameliorates ischemic
contracture and improves the hemodynamic efficacy of chest compression (CC). We cur-
rently investigated whether epinephrine (because of improved myocardial perfusion)
could have similar effects, and compared the effects epinephrine, cariporide, and their
combination using a pig model of VF and closed-chest resuscitation.
Methods: VF was electrically induced in 12 domestic pigs and left untreated for 8 min-
utes. Pigs were randomized to receive at 2 minutes of CC a 3 mg/kg bolus of cariporide
(CARI, n = 4), a 0.02 mg/kg bolus of epinephrine with additional doses if the coronary
perfusion pressure decreased below < 15 mm Hg (EPI, n = 4), or their combination
(CARI/EPI, n = 4). Anterior left ventricular wall thickness was measured using transe-
sophageal echocardiography.
Results: During VF, wall thickness remained largely unchanged. However, during CC a
prominent increase in wall thickness occurred in the EPI but not in the CARI group (Fig-
ure) despite a higher coronary perfusion pressure (36 ± 12 vs 19 ± 6 mm Hg). In the
CARI/EPI group, there were only minimal increases in wall thickness (NS) but a compa-
rable coronary perfusion pressure (36 ± 14 mm Hg).
Conclusion: A combination of cariporide and epinephrine could be beneficial during car-
diac resuscitation by ameliorating ischemic contracture and securing a viable coronary
perfusion pressure. 
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The wearable cardioverter-defibrillator (WCD) is an external device capable of automatic
ventricular tachycardia (VT)/fibrillation (VF) detection and defibrillation. Its effectiveness
in the prevention of arrhythmic sudden death is dependent on patient compliance and
appropriate detection and treatment of VT/VF. We sought to determine whether compli-
ance and effectiveness of anti-arrhythmic treatment by the WCD.
Methods: Patients issued a WCD after market release were entered into a registry,
which recorded baseline demographics and indications, compliance and events.
Results: From August 2002 through July 2003, 218 patients wore the WCD for >7 days
(mean 50.1, range 8-268, total 10917 days). Demographic data were available for 175
patients. The population was predominantly male (72%) with a mean age of 56.6±15.4
yrs (range 83-18, n=151). Indications were available for 119 patients and included post-
MI monitoring (14.2%), post-coronary bypass surgery monitoring (2.5%), bridge to trans-
plant (6.7%), awaiting ICD (49.5%), myocarditis (6.7%), and heart failure (6.6%: ischemic
3.3%, nonischemic 3.3%). Median daily use was 21.5 hrs (90% of time available), mean
19.6±4.6 hrs (82±22%), range 5.2-23.8 hrs. There were no deaths outside the hospital
while the device was not worn. Sustained VT/VF occurred 8 times in 7 patients (3.2%).
First shock success occurred in 8/8. However, 3 patients expired due to subsequent
arrhythmias. In one patient the spouse prevented a second shock. Two patients wearing
the WCD as a bridge after acute MI died: 1 had VT converted by the WCD, recovered
consciousness, but died in an emergency room with VT storm without the WCD; 1 died
with the shock prevented due to an ECG electrodes disturbance, presumably on the
ground or only partially on the skin. Two patients had shocks without an actual arrhyth-
mia. Longer duration of monitoring correlated with higher compliance rates (p<0.001) but
was lower in patients using the WCD as a bridge to transplant (mean 16.5 ± 5.0 hrs/day,
72%, p=0.039).
Conclusions: Compliance was satisfactory with the WCD being worn 90% of the time in
over half of patients. The mortality was 1.4% over a mean usage time of 50 days. Sur-
vival occurred in 62.5% of events.
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BACKGROUND: A major challenge in treating cardiac arrest patients with suspected
pulseless electrical activity (PEA) is determining the presence of cardiac contractility. Evi-
dence of occult blood flow (i.e., "pseudo"-electromechanical dissociation [EMD]) can be
detected using a hand-held peripheral Doppler device, continuous end-tidal carbon diox-
ide monitoring, and transesophageal echocardiography. However, these techniques are
infrequently used due to lack of accuracy, specificity and availability. We hypothesize that
a mobile 2 MHz audible Doppler device could be used to quickly and accurately detect
cardiac contractility in cardiac arrest patients with suspected PEA. METHODS: Hospital-
ized patients in cardiac arrest with the absence of a palpable pulse or blood flow by a
hand-held vascular Doppler device, were evaluated for cardiac contractility using a 2
MHz Doppler head attached to a hand-held Doppler. A subcostal approach similar to that
used in transthoracic echocardiography was employed. Patients were excluded if an
electrocardiogram revealed an arrhythmia not normally associated with a detectable
pulse. RESULTS: To verify accuracy of placement, the Doppler head was placed on vol-
unteers by a technician not able to hear the auditory feedback. An independent observer
confirmed the Doppler tones through a headphone in each of 100 trials. To assess the
sensitivity and specificity of the 2 MHz Doppler, 8 patients with a palpable pulse and 8
patients in asystole were studied. In all 16 cases, a technician was able to correctly iden-
tify the presence or absence of contractility. To evaluate the frequency of cardiac contrac-
tility in cardiac arrest with PEA, we studied 43 patients. Doppler tones were detected in
Baseline Positive 
Troponin
(n = 12,342)
Baseline Negative/
Later Positive 
Troponin
(n = 7,086)
P-value
Aspirin (%) 91.1 91.0 0.76
Heparin (%) 85.2 84.8 0.44
B-blocker (%) 77.8 78.3 0.40
GP IIb-IIIa inhibitor (%) 34.0 34.0 0.98
Cardiac catheterization (%) 65.8 70.2 < 0.001
PCI (%) 36.4 39.7 < 0.001
In-hospital mortality (%) 6.5 4.1 < 0.001
